Can You Get Diabetes From Mounjaro? (October 2026)

01 · The licence

What the licence says about Mounjaro and diabetes

Mounjaro is the brand name for tirzepatide, a once-weekly injection licensed in the UK for weight management in adults and for type 2 diabetes.¹ In type 2 diabetes it improves blood sugar control (HbA1c) and supports weight loss.⁸ A medicine licensed to treat a condition is not designed to cause it.

If you want the full picture of the wider drug class, our guide on GLP-1 medicines and diabetes covers it, and there is a companion piece on developing diabetes while on treatment.

02 · Timing

Why a diagnosis can coincide with starting treatment

Many people who are prescribed Mounjaro for weight management already have weight-related conditions. The licence lists prediabetes and type 2 diabetes among the conditions that can support eligibility at a BMI between 27 and 30.¹¹¹ So a person starting treatment is more likely than average to have blood sugar problems already, whether or not they have been diagnosed yet.

Starting treatment also tends to mean more contact with clinicians and more testing. That can bring an existing condition to light.

03 · Next steps

What to do if you are worried about diabetes

Tell your prescriber about any new or worrying symptoms. If you have severe, persistent stomach pain that may spread to your back, with or without vomiting, pain in the upper right abdomen, fever or yellowing of the skin or eyes, or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing, get medical help straight away. Do not stop or change your dose on your own. If you have a diagnosis of type 2 diabetes, tell your prescriber and your usual diabetes team so care stays joined up.¹

You can also report a suspected side effect through the MHRA Yellow Card scheme.¹⁹ Reports help regulators monitor safety, but a report is not proof of cause.

04 · Getting treatment

How to get Mounjaro safely and what it costs

Mounjaro is prescription-only. Through us it is supplied after a free online consultation reviewed by a GPhC-registered prescriber, and unsuitable orders are refunded automatically. We supply genuine KwikPens through official LillyDirect supply from Eli Lilly's UK distribution. You can check our registration (9012878) on the GPhC register, and we recommend checking any pharmacy that offers to supply without a consultation or prescription.

The Mounjaro pen costs £169.99 at the 2.5mg starting dose. All six doses are in stock. Prices checked 11 October 2026.

Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full. Same-day dispatch applies when you order by 3pm.

05 · How Mounjaro works

How Mounjaro works on blood sugar

Tirzepatide activates two natural gut-hormone receptors at once, GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.¹

That insulin response is why the same medicine is useful in type 2 diabetes. For weight management, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet. This dual action distinguishes Mounjaro from single-action GLP-1 medicines such as semaglutide.

06 · After stopping Mounjaro

Becoming diabetic after stopping Mounjaro

Tirzepatide has a half-life of about five days, so after a final dose it takes roughly 4–5 weeks to clear the system. There is no way to speed this up, and nothing needs doing while it clears.¹ Mounjaro manages weight; it does not cure the biology behind it. In SURMOUNT-4, people who stopped tirzepatide after 36 weeks regained on average 14% of body weight over the following year, while those who continued treatment lost a further 5.5% on average. Stopping should always be planned with your prescriber, with diet and activity habits ready to carry the load.

If you have stopped and develop new symptoms, contact your GP or prescriber. Our pages on coming off Mounjaro and whether withdrawals occur go into what stopping involves.

07 · Who it is licensed for

Who Mounjaro is licensed for

For weight management, Mounjaro is licensed for adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes. It must be used alongside a reduced-calorie diet and increased physical activity.¹¹¹ A prescriber assesses your BMI, medical history and current medicines first.

On the NHS, access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the primary-care rollout began in June 2025 with the highest-need groups first.⁴⁶ Our guides on diabetes medication for weight loss and getting a diabetes drug for weight loss explain the routes.

08 · Weight-loss evidence

What the weight-loss trial showed

In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² For someone starting at 100 kg, 20.9% is about 21 kg.

These are trial averages, and individual results vary. Treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them. This page is information, not a substitute for medical advice.